1-isothiocyanato-4-nitrobenzene

We are 1-isothiocyanato-4-nitrobenzene CAS:2131-61-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1-isothiocyanato-4-nitrobenzene
CAS.NO:2131-61-5
Synonyms:1-isothiocyanato-4-nitrobenzene
4-nitro-phenyl isothiocyanate
p-Nitrophenyl isothiocyanate
4-Nitrophenyl isothiocyanate
Isothiocyanic Acid 4-Nitrophenyl Ester
para-nitrophenylisothiocyanate
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 331.1±25.0 °C at 760 mmHg
Melting Point 110-112 °C(lit.)
Molecular Formula C7H4N2O2S
Molecular Weight 180.184
Flash Point 154.1±23.2 °C
 
Specification:
Appearance:Yellow solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

1-isothiocyanato-4-nitrobenzene


Related News: On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.3-Amino-2-bromo-4-picoline On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.63720-38-7 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).3-bromo-5-fluoro-4-metoxianilina CAS:875664-44-1 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.

Related Products
Product Name
1-bromo-4-iodobutane View Details
1,4-Dioxaspiro[4.5]decan-8-one View Details
1-Chloro-4-fluorobutane View Details
6-chloro-1-hydroxybenzotriazole manufacturer 2-chloro-4-methyl-3-nitropyridine manufacturer 4-Amino Diphenylamine Sulfate manufacturer 4′-Hydroxy-3′-methylacetophenone manufacturer 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol manufacturer